Alemtuzumab

Obinutuzumab is a novel glyca-engineered type II CD20 humanized IgG1 monoclonal antibody for non-Hodgkin lymphoma.Purity&gt:95% (SDS-PAGE&amp:SEC)Endotoxin Level&lt: 1.0EU/mg.

Obinutuzumab is a novel glyca-engineered type II CD20 humanized IgG1 monoclonal antibody for non-Hodgkin lymphoma.Purity&gt:95% (SDS-PAGE&amp:SEC)Endotoxin Level&lt: 1.0EU/mg.

Ozoralizumab (anti-TNF-alpha&HSA).

Ozoralizumab (anti-TNF-alpha&HSA).

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM, targets pleckstrin homology domain of Akt. Phase 3.An alkylphospholipid which inhibits Akt activation and the anti-apoptotic MAPK pathway.

An orally-available, highly selective inhibitor of B-RafV600E (IC₅₀ = 13 nM) less effective against wild type B-Raf (IC₅₀ = 160 nM) as well as several other kinases induces cell cycle arrest and apoptosis in cells and

An orally-available, highly selective inhibitor of B-RafV600E (IC₅₀ = 13 nM) less effective against wild type B-Raf (IC₅₀ = 160 nM) as well as several other kinases induces cell cycle arrest and apoptosis in cells and

An orally-available, highly selective inhibitor of B-RafV600E (IC₅₀ = 13 nM) less effective against wild type B-Raf (IC₅₀ = 160 nM) as well as several other kinases induces cell cycle arrest and apoptosis in cells and

An orally-available, highly selective inhibitor of B-RafV600E (IC₅₀ = 13 nM) less effective against wild type B-Raf (IC₅₀ = 160 nM) as well as several other kinases induces cell cycle arrest and apoptosis in cells and

Praluzatamab (anti-ALCAM) is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab (anti-ALCAM) can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab

Praluzatamab (anti-ALCAM) is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab (anti-ALCAM) can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab

Praluzatamab (anti-ALCAM) is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab (anti-ALCAM) can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab